GlassScriptPhysician profile
Ajay Kumar Pandey
NPI 1124276308
$15,085.04
in general payments reported to CMS, 2019-2025
60 companies · $2,865 in 2025
The $2,865 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $932 · 2021: $2,306 · 2022: $2,080 · 2023: $2,893 · 2024: $2,572 · 2025: $2,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,184 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,184.09 |
| Education | $146.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,689.14 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,293.55 | 2019-2025 | |
| Ucb, INC. | $946.04 | 2019-2025 | Briviact, Rystiggo |
| Neurocrine Biosciences, INC. | $736.01 | 2021-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $665.15 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $657.55 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Pfizer INC. | $546.51 | 2019-2025 | |
| Argenx US, INC. | $486.00 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $467.80 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $466.46 | 2019-2025 | Rytary, Ongentys, Crexont |
| Biogen, INC. | $420.29 | 2020-2025 | Tysabri, Vumerity, Plegridy |
| Amgen INC. | $414.08 | 2019-2025 | Uplizna |
| Lundbeck LLC | $400.06 | 2020-2025 | Rexulti, Vyepti |
| Eisai INC. | $347.49 | 2021-2025 | |
| Sk Life Science, INC. | $344.98 | 2021-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Pandey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.